Dr. Sameh Refat Gaballa, MD

Dr. Gaballa practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Gaballa's NPI, 1659534238, was assigned on July 3, 2008. Dr. Gaballa graduated from Ain Shams University Faculty of Medicine in 2002. Dr. Gaballa's Pennsylvania license number on file is MD444821.

Dr. Gaballa's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Gaballa's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Gaballa to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gaballa practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Gaballa's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Gaballa is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Gaballa's licenses on file in 5 states: Pennsylvania, Florida, Texas, Delaware and New Jersey.

Dmand AI lists anemia, chronic anemia, chronic leukemia, lymphoma, multiple myeloma and neutropenia among the conditions Dr. Gaballa treats.

CMS data shows 256 Medicare services from Dr. Gaballa across 5 procedure codes in 2024, for 147 Medicare patients. Medicare paid $24,769 for them.

CMS counts 147 Medicare patients who saw Dr. Gaballa in 2024. The largest group is 65 to 74, with 75 patients. 75% of them have high cholesterol, and 66% have high blood pressure. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gaballa's median patient age at 69, with 41% women.

In 2024, Dr. Gaballa wrote 270 Medicare Part D claims for 58 patients. 64% of them were for generic drugs. CMS names the drug for 162 of them, across 5 drugs with 11 or more claims each, at $1,124,689 in total drug cost. In 2023, CMS named 111 claims across 6 drugs.

Dr. Gaballa accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gaballa as offering telehealth.

Dmand AI links 32 papers to Dr. Gaballa, published from 2014 to 2024. 2017 was the busiest year, with 7. The most frequent topics are Hematopoietic Stem Cell Transplantation, Antineoplastic Combined Chemotherapy Protocols and Allografts. Dr. Gaballa has published most often in Biol Blood Marrow Transplant. Dr. Gaballa's most frequent co-authors are Richard E. Champlin, MD, Julio C. Chavez, MD and Chitra Hosing, MD.

Dmand AI links Dr. Gaballa to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone and Lymphoma, Non-Hodgkin.

CMS Open Payments shows 207 general payments to Dr. Gaballa from 24 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 45% of the total. ADC Therapeutics America, Inc. paid the most, $60,433.

Dmand AI lists 3 awards for Dr. Gaballa, most recently Trainee Travel Award in 2014.

Dr. Gaballa graduated from Ain Shams University Faculty of Medicine in 2002.

Dr. Gaballa is in network with 10 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.